{
    "nctId": "NCT03358511",
    "briefTitle": "Engineering Gut Microbiome to Target Breast Cancer",
    "officialTitle": "Engineering Gut Microbiome to Target Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "BASIC_SCIENCE",
    "enrollmentCount": 7,
    "primaryOutcomeMeasure": "Mean number of cytotoxic T lymphocytes (CD8+ cells)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Post-menopausal females \u2265 18 years of age\n* Histologically confirmed adenocarcinoma of the breast \u22651.0 cm operable stage I-III\n* Must have adequate organ function,\n* Not receive systemic neoadjuvant therapy\n* Be willing to provide tissue, blood, and stool samples for research study.\n* Must not have taken any probiotics in the past 60 days prior to enrollment.\n\nExclusion Criteria:\n\n* Patients with autoimmune disease, immune deficiency such as HIV, irritable bowel, known diverticulosis, and other serious GI conditions at treating physician's discretion will be excluded.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}